Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different Devices

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male adults of age of 18-45 years.~* Measles immune, as determined by IgG antibody levels.~* Healthy as supported by medical history, physical examination and laboratory evaluation on preset parameters.~* Signed informed consent for participation in trial and for HIV screening.~Exclusion Criteria:~* Medical history of immunodeficiency/suppression or subject with history of close contact with immunocompromised/ immunosuppressed person.~* Chronic administration of immunosuppressants or other immune modifying agents~* Acute febrile illness or suspected measles illness or acute infectious disease~* Acute or chronic, clinically significant pulmonary, endocrine, autoimmune, psychiatric, cardiovascular, neurological, hepatic or renal functional abnormality which in the opinion of the investigator, might interfere with the study objectives~* History of seizure disorders~* Major congenital defects~* Thrombocytopenia or known bleeding disorders 8. History of a previous severe allergic reaction~* Positive serology for HIV antibody, HCV antibody or Hepatitis B surface antigen~* Known hypersensitivity to any component of the study vaccine

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- PMV via Puffhaler® Device (Type: EXPERIMENTAL): The dry powder measles vaccine will be administered via a Puffhaler® device. A single dose of 10 mg will be used.
- PMV via SoloventTM device (Type: EXPERIMENTAL): The dry powder measles vaccine will be administered via a SoloventTM device. A single dose of 10 mg will be used.
- Licensed Subcutaneous Measles Vaccine (Type: ACTIVE_COMPARATOR): Licensed measles vaccine will be administered subcutaneously as single dose of 0.5 ml.

Based on this trial design, predict the completion outcome and termination type (if applicable).